Lower-than-standard dose peg-IFN alfa-2a for chronic hepatitis C caused by genotype 2 and 3 is sufficient when given in combination with weight-based ribavirin

Journal of Viral Hepatitis

Volumn 15, Issue 9, 2008, Pages 641-645

  Weiland, O ^a   Hollander, A ^a   Mattsson, L ^a   Glaumann, H ^a   Lindahl, K ^a   Schvarcz, R ^a   Lindh, G ^a   Enquist, R ^a   Quist, A ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Hepatitis C; Pegylated interferon; Ribavirin; Treatment

Indexed keywords

PEGINTERFERON ALPHA2A; RIBAVIRIN;

ADULT; AGED; ARTICLE; CHRONIC HEPATITIS; CONTROLLED STUDY; DERMATITIS; DIABETES MELLITUS; DRUG DOSE REDUCTION; FEMALE; GENOTYPE; HEPATITIS C; HUMAN; HYPERTHYROIDISM; HYPOTHYROIDISM; MAJOR CLINICAL STUDY; MALE; NEUTROPENIA; PRIORITY JOURNAL; SARCOIDOSIS; THROMBOCYTOPENIA; TREATMENT RESPONSE; VIRUS LOAD;

ADULT; AGED; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HEPATITIS C; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2A; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; RIBAVIRIN; RNA, VIRAL; TREATMENT OUTCOME; VIRAL LOAD;

EID: 49649127666     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/j.1365-2893.2008.00999.x     Document Type: Article

References (23)

1. Anonymous. NIH consensus development conference statement: management of hepatitis C 2002 (June 10-12, 2002). Hepatology 2002 36 (Suppl. 1 S3 S20.
2. Fried MW, Shiffman ML, Reddy KR et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002 347 (13 975 982.
3. Hadziyannis SJ, Sette H Jr., Morgan TR et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004 140 (5 346 355.
4. Manns MP, McHutchison JG, Gordon SC et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001 358 (9286 958 965.
5. Lindsay KL, Trepo C, Heintges T et al. A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C. Hepatology 2001 34 (2 395 403.
6. Pockros PJ, Carithers R, Desmond P et al. Efficacy and safety of two-dose regimens of peginterferon alpha-2a compared with interferon alpha-2a in chronic hepatitis C: a multicenter, randomized controlled trial. Am J Gastroenterol 2004 99 (7 1298 1305.
7. Weiland O, Schvarcz R, Mattsson L et al. 135 μg peg-IFN in combination with weight-based ribavirin for genotype 2 and 3 is highly efficacious. J Hepatol 2006 44 (Suppl. 2 S230.
8. Weiland O, Hollander A, Frisell K, Sandell S. Cost-effective therapy for genotype 2 and 3 chronic hepatitis C. Hepatology 2003 38 (Suppl. 1 739A.
9. Dalgard O, Bjoro K, Hellum KB et al. Treatment with pegylated interferon and ribavarin in HCV infection with genotype 2 or 3 for 14 weeks: a pilot study. Hepatology 2004 40 (6 1260 1265.
10. Yu ML, Dai CY, Huang JF et al. A randomised study of peginterferon and ribavirin for 16 vs 24 weeks in patients with genotype 2 chronic hepatitis C. Gut 2007 56 (4 553 559. Epub 2006 Sep 6.
11. von Wagner M, Huber M, Berg T et al. Peginterferon-alpha-2a (40 KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C. Gastroenterology 2005 129 (2 522 527.
12. Mangia A, Santoro R, Minerva N et al. Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3. N Engl J Med 2005 352 (25 2609 2617.
13. Zeuzem S, Buti M, Ferenci P et al. Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia. J Hepatol 2006 44 (1 97 103.
14. Jensen DM, Morgan TR, Marcellin P et al. Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapy. Hepatology 2006 43 (5 954 960.
15. Shiffman M, Pappas S, Nyberg L et al. Peginterferon alpha-2a for 16 or 24 weeks in patients with HCV genotypes 2 or 3. Final results of the accelerate study. J Hepatol 2006 44 (Suppl. 2 S271.
16. Sizmann D, Boeck C, Boelter J et al. Fully automated quantification of hepatitis C virus (HCV) RNA in human plasma and human serum by the COBAS((R)) AmpliPrep/COBAS((R)) TaqMan((R)) System. J Clin Virol 2007 38 (4 326 333.
17. Stuyver L, Wyseur A, van Arnhem W, Hernandez F, Maertens G. Second-generation line probe assay for hepatitis C virus genotyping. J Clin Microbiol 1996 34 (9 2259 2266.
18. Yun Z, Lara C, Johansson B, Lorenzana de Rivera I, Sonnerborg A. Discrepancy of hepatitis C virus genotypes as determined by phylogenetic analysis of partial NS5 and core sequences. J Med Virol 1996 49 (3 155 160.
19. Hollander A, Glaumann H, Weiland O. Histological findings, genotype distribution and percentage of patients fulfilling the treatment criteria among patients with chronic hepatitis C virus infection in a single Swedish centre. Scand J Gastroenterol 2004 39 (2 164 167.
20. Wejstal R, Alaeus A, Fischler B, Reichard O, Uhnoo I, Weiland O. Chronic hepatitis C: updated Swedish consensus. Scand J Infect Dis 2003 35 (8 445 451.
21. Dalgard O, Mangia A. Short-term therapy for patients with hepatitis C virus genotype 2 or 3 infection. Drugs 2006 66 (14 1807 1815.
22. Mangia A. Short-duration therapy for hepatitis C: suitable for all? J Viral Hepat 2007 14 (4 221 227.
23. Lidgren M, Hollander A, Weiland O, Jönsson B. Productivity improvements in hepatitis C treatment: impact on efficacy, cost, cost-effectiveness and quality of life. Scand J Gastroenterol 2007 42 : 867 877.